New RANO 2.0 and Oncology Trial Endpoints
The updated RANO 2.0 criteria from the Response Assessment in Neuro-Oncology (RANO) group introduce refined guidelines for assessing central nervous system (CNS) tumors, particularly gliomas. These updates are crucial for clinical trials, influencing imaging-based endpoints and data collection strategies. In this webinar, MERIT will explore the principles and recommendations of RANO 2.0, focusing on its impact on clinical trial design, imaging assessments, and electronic case report form (eCRF) data collection to ensure accurate response evaluation.
3 key questions that are answered:
- What key imaging and clinical elements must be collected in the eCRF when applying RANO 2.0?
- How are imaging-based endpoints derived from RANO 2.0, and how does it compare to previous RANO criteria?
- What challenges and special considerations arise when implementing RANO 2.0 in clinical trials?
Gene Kim, PharmDASSOCIATE DIRECTOR OF MEDICAL AFFAIRS & INNOVATION, ONCOLOGY
Gene is MERIT’s Associate Director of Medical Affairs & Innovation for our oncology division. He provides subject matter expertise and helps design and configure MERIT’s flexible oncology reading platform to accommodate various reading paradigms. Gene has experience in evidence-based patient care and academic research, a background in pharmacy, and 6 years supporting clinical trials. He implements software workflows to support oncology trials with response criteria such as RECIST 1.1, iRECIST, Lugano, and RANO, and helps to increase the efficiency and accuracy of clinical data collection for imaging endpoints. Gene received his Doctor of Pharmacy (Pharm.D.) from the University of Wisconsin-Madison and has a bachelor’s degree in Neurobiology.
Christopher SylviaOncology Associate, MERIT
Chris identifies and analyzes oncology client clinical trial needs on the East Coast, offering tailored solutions that align with MERIT’s capabilities. He collaborates with internal teams to ensure that there is alignment between all stakeholders, ensuring compliance, quality, and clarity in the imaging data results.